Jeremy G. Ardanuy

Jeremy G. Ardanuy serves as a Researcher in the Department of Microbiology and Immunology at the University of Maryland, Baltimore School of Medicine, where he investigates respiratory viral pathogenesis and therapeutic development. His work focuses on coronaviruses and influenza within the Center for Pathogen Research, utilizing advanced models to study host-pathogen interactions and identify novel treatment strategies.

Education:

• BS in Cellular Biology and Molecular Genetics, University of Maryland College Park (2011-2015)
• PhD in Molecular Microbiology and Immunology, University of Maryland School of Medicine (2015-2020)
• Postdoctoral Fellowship, Lab of Dr. Matthew Frieman, Center for Pathogen Research (2021-2023)

Dr. Ardanuy's research centers on viral pathogenesis mechanisms in highly pathogenic coronaviruses (SARS-CoV-2, MERS, SARS-CoV) and influenza, with emphasis on host immune evasion tactics and inflammatory responses. He employs cellular models, in vivo mouse systems, and airway-liquid interface organoids to identify therapeutic targets that modulate host immune pathways rather than directly targeting viruses. His work particularly examines how comorbidities like diabetes and asthma alter disease progression and treatment efficacy.

Analysis of his 15 most recent publications reveals consistent focus on coronavirus therapeutics (7 articles), host-pathogen interactions in respiratory pathogens (5), and innovative antiviral strategies including drug repurposing and combination therapies. Key trends include development of host-directed antivirals, investigation of metabolic comorbidities on infection outcomes, and exploration of interferon signaling pathways in viral pathogenesis.

Scientific Awards:

• T32 Infection and Immunity training grant (2017-2018)
• J. Howard Brown award, American Society of Microbiology (2018)
• F31 Fellowship grant, NIAID (2018-2020)
• T32 Signaling Pathways in Innate Immunity (2020-2021)

Dr. Ardanuy has secured significant NIH funding through F31 and T32 mechanisms supporting his postdoctoral and early-career research. While no formal student advisees are documented, his collaborative work appears across multiple laboratories within the Department of Microbiology and Immunology. Current grant activities focus on host-directed therapies for emerging respiratory viruses and mechanisms of viral immunopathology.

He conducts research within the Center for Pathogen Research under Dr. Matthew Frieman's mentorship, utilizing specialized facilities for BSL-3 coronavirus work, in vivo mouse infection models, and advanced organoid systems. His team collaborates extensively with virology and immunology specialists across the University of Maryland campus to develop therapeutic interventions for high-consequence respiratory pathogens.